logo-loader
viewOragenics Inc

Oragenics working on treatment for oral mucositis with promising AG013 product

Oragenics (NYSE: OGEN) CEO Alan Joslyn talked with Proactive’s Steve Darling at the 12th annual LD Micro Conference. The Tampa, Florida, company develops antibiotics against infectious diseases. It is developing AG013, which is in clinical trials for the treatment of oral mucositis, or ulcerative lesions in patients with cancer. 

Quick facts: Oragenics Inc

Price: 0.9081 USD

NYSE:OGEN
Market: NYSE
Market Cap: $55.3 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

VolitionRX progressing towards launch of first commercial products using...

VolitionRx Limited's (NYSEAMERICAN:VNRX) Cameron Reynolds tells Proactive the firm rounded out the second quarter with $21.3 million in cash and equivalents compared to $12 million in the same quarter a year ago. The company's now tested two independent cohorts of COVID-19 positive patients with...

12 hours, 9 minutes ago

2 min read